News | August 10, 2025
Aurobindo Pharma Q1 FY26 PAT slips 10% YoY to Rs. 824 Cr
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
With this addition, the company’s total Installed MCC Capacity will rise to 30,000 MTPA
IOLCP has reported total income of Rs. 559.06 crores during the period ended June 30, 2025
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
Vasograin Plus represents a major advancement in the treatment of migraine
Subscribe To Our Newsletter & Stay Updated
